Plain-English translation of NCT05010681 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase II trial testing combined with in people whose advanced liver cancer stopped responding to previous immune checkpoint inhibitor treatment. Both of these medications have shown promise on their own, and this study is checking whether giving them together works better. The trial is recruiting 25 people with either hepatocellular carcinoma or intrahepatic cholangiocarcinoma that cannot be surgically removed.
When advanced liver cancer progresses despite immune therapy, patients urgently need new options. This medication combination is being tested because each drug has shown activity against liver cancer, and combining them may offer better results for people whose disease has stopped responding to prior treatment.
You likely qualify if…
You likely don't qualify if…
You would take and as part of this study. The trial involves regular clinic visits for physical exams, blood tests, and imaging scans (CT or MRI) to monitor how your cancer responds to the medication. You'll need to comply with the study schedule, maintain accurate records of your medication use, and follow contraception guidelines if applicable. The study is actively recruiting, so your care team can discuss the exact visit schedule and duration with you during enrollment.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
China